MedTrace Logo

Impact of Risk for OSA in Lung Cancer

NCT04003961 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2022-01-04

No results posted yet for this study

Summary

Background: Previous studies have reported that intermittent hypoxia in obstructive sleep apnea (OSA) is associated with tumor progression, metastasis and treatment outcomes. However, studies explaining the relationships between specific types of cancer and OSA are needed. In this study, it is aimed to show the effect of excessive daytime sleepiness as determined by Epworth sleepiness scale(ESS) and the effect of OSA risk determined by STOP BANG questionnaire on survival and treatment outcomes in lung cancer.

Method: The patients who admit the palliative care outpatient clinic of our hospital with the diagnosis of lung cancer (stage 3 and stage 4 non-small cell lung cancer or limited / extensive stage small cell lung cancer) between July 2019-2020 will be assessed for excessive daytime sleepiness(EDS) and risk of obstructive sleep apnea (OSA) by Epworth sleepiness scale and the STOP-BANG questionnaire. The patients will be grouped according to the risk of OSA and EDS.Total / progression-free survival, treatment outcomes and side effects of the treatment will be evaluated comparatively.

Conditions

Interventions

OTHER

STOP- BANG Questionnaire and Epworth sleepiness scale

STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes

Sponsors & Collaborators

  • Atatürk Chest Diseases and Chest Surgery Training and Research Hospital

    lead OTHER

Principal Investigators

  • Sezgi Şahin Duyar, MD · Atatürk Chest Diseases and Thoracic Surgery Traininig and Research Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04003961 on ClinicalTrials.gov